Back to Journals » International Journal of Nanomedicine » Volume 5

Recent advances in PEG–PLA block copolymer nanoparticles

Authors Xiao RZ, Zeng Z, Zhou GL, Wang JJ, Li FZ, Wang AM

Published 26 November 2010 Volume 2010:5 Pages 1057—1065


Review by Single anonymous peer review

Peer reviewer comments 4

Ren Zhong Xiao1, Zhao Wu Zeng1,2, Guang Lin Zhou1, Jun Jie Wang1, Fan Zhu Li2, An Ming Wang1
1Research Center for Biomedicine and Health, Hangzhou Normal University, Hangzhou, Zhejiang, China; 2College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Abstract: Due to their small particle size and large and modifiable surface, nanoparticles have unique advantages compared with other drug carriers. As a research focus in recent years, polyethylene glycol–polylactic acid (PEG–PLA) block copolymer and its end-group derivative nanoparticles can enhance the drug loading of hydrophobic drugs, reduce the burst effect, avoid being engulfed by phagocytes, increase the circulation time of drugs in blood, and improve bioavailability. Additionally, due to their smaller particle size and modified surface, these nanoparticles can accumulate in inflammation or target locations to enhance drug efficacy and reduce toxicity. Recent advances in PEG–PLA block copolymer nanoparticles, including the synthesis of PEG–PLA and the preparation of PEG–PLA nanoparticles, were introduced in this study, in particular the drug release and modifiable characteristics of PEG–PLA nanoparticles and their application in pharmaceutical preparations.

Keywords: PEG–PLA, block copolymer, nanoparticles, drug delivery system

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.